Business Context and Reporting Period
This Form 8-K is filed by Aquinox Pharmaceuticals, Inc. (not Neurogene Inc.) on November 10, 2015. The report announces the issuance of a press release detailing financial results for the third quarter ended September 30, 2015. The full text of the press release is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the third quarter of 2015 were announced.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information is furnished but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Locate and review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended September 30, 2015.
- Confirm the legal status of the data, noting the disclaimer that the press release is not deemed "filed" under Section 18 of the Exchange Act.